Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "PGMS-pathway control state"

From Bioblast
Line 35: Line 35:
::::* DL-Protocol for permeabilized fibers (pfi): [[SUIT-001 O2 pfi D002]]
::::* DL-Protocol for permeabilized fibers (pfi): [[SUIT-001 O2 pfi D002]]
::::* DL-Protocol for permeabilized cells (pce): [[SUIT-001 O2 ce-pce D003]]
::::* DL-Protocol for permeabilized cells (pce): [[SUIT-001 O2 ce-pce D003]]
::::* DL-Protocol for permeabilized PBMCs and PLTs: [[SUIT-001 O2 ce-pce D004]]
::::* DL-Protocol for permeabilized PBMC and PLT: [[SUIT-001 O2 ce-pce D004]]
:::*[[SUIT-008]]
:::*[[SUIT-008]]
::::* DL-Protocol for permeabilized fibers (pfi): [[SUIT-008 O2 pfi D014]]
::::* DL-Protocol for permeabilized fibers (pfi): [[SUIT-008 O2 pfi D014]]

Revision as of 09:44, 3 March 2020


high-resolution terminology - matching measurements at high-resolution


PGMS-pathway control state

Description

PGMS

PGMS: Pyruvate & Glutamate & Malate & Succinate.

MitoPathway control state: NS-pathway control state

2-oxoglutarate is produced through the citric acid cycle from citrate by isocitrate dehydrogenase, from oxaloacetate and glutamate by the transaminase, and from glutamate by the glutamate dehydrogenase. If the 2-oxoglutarate carrier does not outcompete these sources of 2-oxoglutarate, then the TCA cycle operates in full circle with external pyruvate&malate&glutamate&succinate

Abbreviation: PGMS

Reference: Gnaiger 2014 MitoPathways - Chapter 5.6


MitoPedia concepts: SUIT state 

More details
Β» NS-pathway control state
Β» Additive effect of convergent electron flow
Β» Respiratory complexes - more than five
Β» Convergent electron flow


PGMSL

PGMS pathway in the LEAK state can be evaluated in the following SUIT protocols:


PGMSP

PGMS pathway in the OXPHOS state can be evaluated in the following SUIT protocols:

PGMSE

PGMS pathway in the ET state can be evaluated in the following SUIT protocols:

Discussion

Recent studies showed that S- and NS-linked OXPHOS capacity is inhibited by 2 mM malate concentrations as applied in many SUIT protocols. This inhibition is less pronounced at higher succinate concentrations (10 mM up to 50 mM S).